title: A novel canine model of partial outlet obstruction secondary to prostatic hypertrophy.
abstract: Benign prostatic hyperplasia (BPH) is a major medical problem in the United States. The primary medical complication of BPH is progressive obstruction of the urethra and a subsequent in reduction the ability or the bladder to empty efficiently. The urodynamic characteristics associated with BPH include hyperreflexia, increased bladder capacity, increased frequency, decreased flow rate, and increased residual volume. Although there currently are individual animal models of prostate enlargement and animal models of partial outlet obstruction, there is no model of progressive obstruction secondary to prostate enlargement. The primary objective of the current study was to develop a canine model of BPH that would secondarily result in partial urethral obstruction and impaired urodynamics. Our model consists of encapsulating the prostate in a nylon mesh to prevent the growth of the prostate into the peritoneal cavity and then treating the dog with steroids to induce prostate growth and subsequently produce urethral constriction. The results demonstrate that encapsulation of the dog prostate and administration of steroids results in an increase in prostate mass simultaneously with an increase in urethral pressure and in changes in bladder contraction consistent with the presence of partial outlet obstruction. This preliminary study demonstrates that by preventing the outward growth of the steroid-stimulated prostate, urethral obstruction resembling BPH can be produced.
authors.affiliation: Division of Urology, University of Pennsylvania School of Medicine, Philadelphia.
authors.forename: G A
authors.initials: GA
authors.lastname: Broderick
authors.forename: P A
authors.initials: PA
authors.lastname: Longhurst
authors.forename: P E
authors.initials: PE
authors.lastname: Juniewicz
authors.forename: A J
authors.initials: AJ
authors.lastname: Wein
authors.forename: R M
authors.initials: RM
authors.lastname: Levin
mesh_terms: D000818:Animals; D003131:Combined Modality Therapy; D004195:Disease Models, Animal; D004285:Dogs; D004343:Drug Implants; D006728:Hormones / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D009119:Muscle Contraction / Q000502:physiology; D009929:Organ Size; D011312:Pressure; D011467:Prostate / Q000187:drug effects / Q000254:growth & development; D011470:Prostatic Hyperplasia / Q000150:complications* / Q000473:pathology / Q000503:physiopathology / Q000628:therapy; D013526:Surgical Mesh; D014524:Urethral Obstruction / Q000209:etiology* / Q000473:pathology / Q000503:physiopathology / Q000628:therapy
chemical_list: D004343:Drug Implants; D006728:Hormones